202 related articles for article (PubMed ID: 24240607)
1. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.
Stallinger S; Eller N; Högenauer C
Wien Klin Wochenschr; 2014 Jan; 126(1-2):9-14. PubMed ID: 24240607
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin in the management of colonic diverticular disease.
Latella G; Scarpignato C
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
Brandimarte G; Tursi A
Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE).
Cuomo R; Barbara G; Annibale B
Dig Liver Dis; 2017 Jun; 49(6):595-603. PubMed ID: 28215517
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
Papi C; Ciaco A; Koch M; Capurso L
Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease.
Colecchia A; Vestito A; Pasqui F; Mazzella G; Roda E; Pistoia F; Brandimarte G; Festi D
World J Gastroenterol; 2007 Jan; 13(2):264-9. PubMed ID: 17226906
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
Tursi A; Brandimarte G; Daffinà R
Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.
Papi C; Ciaco A; Koch M; Capurso L
Ital J Gastroenterol; 1992 Oct; 24(8):452-6. PubMed ID: 1330083
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
Di Mario F; Aragona G; Leandro G; Comparato G; Fanigliulo L; Cavallaro LG; Cavestro GM; Iori V; Maino M; Moussa AM; Gnocchi A; Mazzocchi G; Franzé A
Dig Dis Sci; 2005 Mar; 50(3):581-6. PubMed ID: 15810646
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy: rifaximin-α and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease.
Pietrzak AM; Banasiewicz T; Skoczylas K; Dziki A; Szczepkowski M
Pol Przegl Chir; 2020 Apr; 92(2):22-28. PubMed ID: 32312914
[TBL] [Abstract][Full Text] [Related]
12. Non-absorbable antibiotics in the treatment of diverticular disease of the colon.
Papi C; Camarri E
Ital J Gastroenterol; 1992; 24(9 Suppl 2):19-22. PubMed ID: 1336684
[TBL] [Abstract][Full Text] [Related]
13. The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis.
Banasiewicz T; Francuzik W; Bobkiewicz A; Krokowicz Ł; Borejsza-Wysocki M; Paszkowski J; Studniarek A; Krokowicz P; Grochowalski M; Szczepkowski M; Lorenc Z
Pol Przegl Chir; 2017 Feb; 89(1):22-31. PubMed ID: 28522790
[TBL] [Abstract][Full Text] [Related]
14. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.
Pimentel M; Park S; Mirocha J; Kane SV; Kong Y
Ann Intern Med; 2006 Oct; 145(8):557-63. PubMed ID: 17043337
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
[TBL] [Abstract][Full Text] [Related]
16. [Role of rifaximin in the treatment of colonic diverticular disease].
Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
[TBL] [Abstract][Full Text] [Related]
17. Summaries for patients. Can antibiotics improve the symptoms of the irritable bowel syndrome?
Ann Intern Med; 2006 Oct; 145(8):I24. PubMed ID: 17043334
[No Abstract] [Full Text] [Related]
18. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
Prantera C; Lochs H; Grimaldi M; Danese S; Scribano ML; Gionchetti P;
Gastroenterology; 2012 Mar; 142(3):473-481.e4. PubMed ID: 22155172
[TBL] [Abstract][Full Text] [Related]
19. Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease.
Pandolfi F; Frosali S; Petruzziello L; Newton EE; Costamagna G
Mini Rev Med Chem; 2015; 16(3):218-21. PubMed ID: 26202195
[TBL] [Abstract][Full Text] [Related]
20. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms.
Di Stefano M; Strocchi A; Malservisi S; Veneto G; Ferrieri A; Corazza GR
Aliment Pharmacol Ther; 2000 Aug; 14(8):1001-8. PubMed ID: 10930893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
